Bacterial Lysate Complex Administered Intranasally Suppresses Inflammation in an In Vivo Model of Aseptic Lymphadenitis

Bull Exp Biol Med. 2022 Jul;173(3):361-365. doi: 10.1007/s10517-022-05549-5. Epub 2022 Jul 19.

Abstract

The effect of a bacterial lysate complex IRS 19 on local and systemic manifestations of inflammation was studied in a rat model of aseptic lymphadenitis. Injection of λ-carrageenan into the cervical lymph node via surgical approach caused an increase in the thickness of the capsule, disturbances in histoarchitecture, the appearance of necrosis foci, histiocytosis of subcapsular and cerebral sinuses in the lymph node, as well as an increase in the level of TNFα in the blood serum and the number of circulating leukocytes and neutrophils. Course intranasal administration of bacterial lysate complex in this model dose-dependently reduced the level of these markers of the systemic inflammatory response and the severity of microstructural disorders in the affected lymph nodes. Thus, bacterial lysate complex after intranasal administration produces a systemic anti-inflammatory effect that goes beyond the respiratory tract.

Keywords: IRS 19; anti-inflammatory effect; aseptic lymphadenitis; bacterial lysate.

MeSH terms

  • Animals
  • Cell Extracts
  • Inflammation / drug therapy
  • Lymph Nodes / pathology
  • Lymphadenitis* / drug therapy
  • Lymphadenitis* / pathology
  • Neutrophils / pathology
  • Rats

Substances

  • Broncho-Vaxom
  • Cell Extracts